448 related articles for article (PubMed ID: 8531860)
1. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
2. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
3. [Hearing loss caused by high dose carboplatin therapy].
Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
[TBL] [Abstract][Full Text] [Related]
4. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.
Parsons SK; Neault MW; Lehmann LE; Brennan LL; Eickhoff CE; Kretschmar CS; Diller LR
Bone Marrow Transplant; 1998 Oct; 22(7):669-74. PubMed ID: 9818694
[TBL] [Abstract][Full Text] [Related]
5. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
6. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.
Gardner SL; Asgharzadeh S; Green A; Horn B; McCowage G; Finlay J
Pediatr Blood Cancer; 2008 Aug; 51(2):235-40. PubMed ID: 18381756
[TBL] [Abstract][Full Text] [Related]
7. The incidence of hearing impairment after successful treatment of neuroblastoma.
Simon T; Hero B; Dupuis W; Selle B; Berthold F
Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
[TBL] [Abstract][Full Text] [Related]
8. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
Zacharoulis S; Levy A; Chi SN; Gardner S; Rosenblum M; Miller DC; Dunkel I; Diez B; Sposto R; Ji L; Asgharzadeh S; Hukin J; Belasco J; Dubowy R; Kellie S; Termuhlen A; Finlay J
Pediatr Blood Cancer; 2007 Jul; 49(1):34-40. PubMed ID: 16874765
[TBL] [Abstract][Full Text] [Related]
9. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
[TBL] [Abstract][Full Text] [Related]
10. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
11. Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue.
Fangusaro JR; Jubran RF; Allen J; Gardner S; Dunkel IJ; Rosenblum M; Atlas MP; Gonzalez-Gomez I; Miller D; Finlay JL
Pediatr Blood Cancer; 2008 Mar; 50(3):715-7. PubMed ID: 17009232
[TBL] [Abstract][Full Text] [Related]
12. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children.
Macdonald MR; Harrison RV; Wake M; Bliss B; Macdonald RE
J Otolaryngol; 1994 Jun; 23(3):151-9. PubMed ID: 8064951
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
Fangusaro J; Finlay J; Sposto R; Ji L; Saly M; Zacharoulis S; Asgharzadeh S; Abromowitch M; Olshefski R; Halpern S; Dubowy R; Comito M; Diez B; Kellie S; Hukin J; Rosenblum M; Dunkel I; Miller DC; Allen J; Gardner S
Pediatr Blood Cancer; 2008 Feb; 50(2):312-8. PubMed ID: 17668858
[TBL] [Abstract][Full Text] [Related]
14. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
Lambert MP; Shields C; Meadows AT
Pediatr Blood Cancer; 2008 Feb; 50(2):223-6. PubMed ID: 17278120
[TBL] [Abstract][Full Text] [Related]
17. Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.
Ilveskoski I; Saarinen UM; Wiklund T; Perkkiö M; Salmi TT; Lanning M; Mäkipernaa A; Pihko H
Med Pediatr Oncol; 1996 Jul; 27(1):26-31. PubMed ID: 8614387
[TBL] [Abstract][Full Text] [Related]
18. [Monitoring hearing during ototoxic cisplatin therapy].
Kluba J; Kluba U; von Specht H; Mittler U
Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815
[TBL] [Abstract][Full Text] [Related]
19. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
Broun ER; Nichols CR; Mandanas R; Salzman D; Turns M; Hromas R; Cornetta K; Einhorn LH
Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
